



4,000 enrollments

to the LUNGMAP Screening Study —
thank you for helping us achieve this milestone!

Lung-MAP After Progression on Targeted Therapy

More than one-third of people with non-small cell lung cancer (NSCLC) have a genomic alteration that a targeted therapy can treat. But in most of these cases, the cancer eventually develops resistance to that therapy, leaving patients with limited treatment options.

In Lung-MAP, these patients now have **2 sub-study options** after progression.

S1900G

S1900G is for patients who have NSCLC with an EGFR mutation whose cancer progressed on osimertinib and who have any level of MET amplification *after progression*.

MET amplification can be identified via liquid biopsy (ctDNA) or tissue testing after progression on osimertinib.

If your patient has advanced NSCLC with an EGFR mutation and is currently on osimertinib, **remember to test for MET amplification at progression**.

S1900N — Now Open!

S1900N is for patients who have NSCLC with an actionable genomic alteration and aren't eligible for other biomarker-driven Lung-MAP sub-studies.

The study is enrolling patients with NSCLC previously treated with a targeted therapy and platinum-based chemotherapy.

It compares 3 treatment plans:

sacituzumab govitecan
+ ivonescimab


sacituzumab govitecan

ivonescimab

Eligible alterations include *ALK, EGFR, HER2, MET, NTRK, RET, and ROS1*. Eligibility is broad, and patients' tissue or blood can be screened using existing next-generation sequencing (NGS) results or new NGS testing.

Lung-MAP continues to evolve to meet the needs of patients with advanced NSCLC, including developing new treatment options to follow targeted therapy.

Schema of Actively Accruing Sub-Studies



How many sub-studies does your site have open?

Open all Lung-MAP sub-studies to give your patients the most options.

**MARK YOUR
CALENDAR!**

SWOG Group Meeting
October 8–10, Chicago

Lung-MAP Update Forum
October 9, 4:15–5:45 pm CT
attend in-person or via Zoom



REGISTER HERE

Keep your colleagues in the loop!

Send their emails to communications@swog.org to sign them up for the Lung-MAP newsletter.

Lung-MAP Questions?

Regulatory, Protocol, or Consent: Protocols@swog.org

Eligibility, RAVE, or Data: LUNGMAPquestion@crab.org

NGS Testing: LungmapNGS@swog.org

Central Monitoring: CentralMonitorQuestion@swog.org

Quality Assurance Auditing: QAmail@swog.org

Funding: Funding@swog.org

Lung-MAP Enrollment Leaders

JULY 1, 2025 – JUNE 30, 2026

INVESTIGATORS

Toni Pacioles	Edwards Comprehensive Cancer Center (WV)	11
Ivy Riano Monsalve	Dartmouth Hitchcock Medical Center – Dartmouth Cancer Center (NH)	9
Moises Harari-Turquie	University of New Mexico Cancer Center (NM)	9
Nisha Mohindra	Northwestern University (IL)	7
Paul Paik	Memorial Sloan Kettering Cancer Center (NY), MSK Nassau (NY), and MSK Basking Ridge (NJ)	7
John Villano	University of Kentucky – Markey Cancer Center (KY)	7
Kim-Son Nguyen	Palo Alto Medical Foundation – Sunnyvale (CA)	6
Martha Mapalo	University of New Mexico Cancer Center (NM)	6
Rohan Ahluwalia	Palo Alto Medical Foundation – Santa Cruz (CA)	6
Yifan Tu	Mercy Hospital South (MO)	6

RESEARCH ASSOCIATES

Selina Perez	Palo Alto Medical Foundation – Santa Cruz (CA) and Palo Alto Medical Foundation – Sunnyvale (CA)	13
Nerissa Charland	Dartmouth Hitchcock Medical Center – Dartmouth Cancer Center (NH) and Dartmouth Cancer Center – North (VT)	12
Michele Kildare	Palo Alto Medical Foundation – Santa Cruz (CA) and Palo Alto Medical Foundation – Sunnyvale (CA)	11
Kimberly Flores	University of New Mexico Cancer Center (NM)	10
Manpreet Bangian	Northwestern University (IL)	9
Abigail Cornette	University of Kentucky – Markey Cancer Center (KY)	8
Laura O'Brien	Mercy Hospital South (MO)	8
Christos Derizotis	University of New Mexico Cancer Center (NM)	7
Kathreena Alapatt	Memorial Sloan Kettering Cancer Center (NY), MSK Nassau (NY), and MSK Basking Ridge (NJ)	7
Keshia Bowen	Edwards Comprehensive Cancer Center (WV)	7

SITES

Edwards Comprehensive Cancer Center (WV)	17
University of New Mexico Cancer Center (NM)	15
Palo Alto Medical Foundation – Sunnyvale (CA)	13
Dartmouth Hitchcock Medical Center – Dartmouth Cancer Center (NH)	12
Palo Alto Medical Foundation – Santa Cruz (CA)	12
University of Kentucky – Markey Cancer Center (KY)	12
Northwestern University (IL)	10
Northside Hospital (GA)	9
Mercy Hospital South (MO)	8
Ridley-Tree Cancer Center (CA)	8

SITES BY SUB-STUDY

S1800E (2-way tie)
University of Kentucky – Markey Cancer Center (KY)
Dartmouth Hitchcock Medical Center – Dartmouth Cancer Center (NH)
S1900G
Fred Hutch Cancer Center (WA)
S1900J (4-way tie)
Baptist Memorial Hospital and Cancer Center – Desoto (MS)
Queen's Medical Center (HI)
Rocky Mountain Regional VA Medical Center (CO)
Sechler Family Cancer Center (PA)
S1900K
Memorial Sloan Kettering Cancer Center (NY)